Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: results of a pilot study in four patients.
The effect of low-dose cytosine arabinoside (10 mg/m2 q 12 h for 21 days) was evaluated in four patients with acute myelocytic leukemia. Neither were significant changes in the percentage of leukemic cells in the bone marrow noted, nor were there any signs of a percentual increase of differentiated cells. The total observation time was 60 days. In the blood the absolute number of leukemic cells showed a significant increase. In conclusion, no complete or partial remissions were achieved.
D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male
D003561:Cytarabine